Profile data is unavailable for this security.
About the company
Valerio Therapeutics SA formerly Onxeo SA is a France-based clinical-stage biotechnology company. The company targets tumor DNA functions through unparalleled mechanisms of action in the sought-after field of DNA damage response (DDR). It aims at holding a portfolio of advanced programs targeting severe pathologies with unmet clinical needs. It has two programs in clinical development stage: Livatag, a doxorubicin Transdrag in Phase III, for the treatment of primary liver cancer, and Validive, a clonidine Lauriad in Phase II, for treatment of radio/chemo-induced severe oral mucositis at patients with head and neck cancer. It also has one registered product in the United States, Beleodaq/ belinostat, for the treatment of peripheral T-Cell lymphoma (PTCL) and opportunities for further development; and two initial drugs registered in Europe and the United States: Loramyc/ Oravig for the treatment of oropharyngeal candidiasis, and Sitavig for the treatment of recurring herpes labialis.
- Revenue in EUR (TTM)1.83m
- Net income in EUR-13.17m
- Incorporated1997
- Employees25.00
- LocationValerio Therapeutics SA49 boulevard du General Martial ValinPARIS 75015FranceFRA
- Phone+33 145587600
- Fax+33 145580881
- Websitehttps://www.onxeo.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aelis Farma SA | 446.00k | -8.20m | 18.85m | 26.00 | -- | 3.08 | -- | 42.26 | -0.5998 | -0.5998 | 0.0326 | 0.4461 | 0.0247 | -- | 0.5826 | 17,153.85 | -45.48 | -24.79 | -64.80 | -40.70 | -- | -- | -1,837.89 | -115.10 | -- | -- | 0.4907 | -- | -70.42 | -- | -46.83 | -- | 39.47 | -- |
| NicOx SA | 3.32m | -27.06m | 30.78m | 11.00 | -- | -- | -- | 9.28 | -0.3657 | -0.3657 | 0.045 | -0.0659 | 0.1034 | -- | 1.63 | 663,166.00 | -84.36 | -28.03 | -91.95 | -30.66 | -- | -- | -816.13 | -338.04 | -- | -56.80 | 1.48 | -- | 13.85 | 2.77 | -7.22 | -- | -- | -- |
| Advicenne SA | -100.00bn | -100.00bn | 30.83m | 15.00 | -- | -- | -- | -- | -- | -- | -- | -1.95 | -- | -- | -- | -- | -- | -61.16 | -- | -123.11 | -- | -258.05 | -- | -431.56 | 0.4485 | -- | -- | -- | 4.76 | 9.63 | 14.14 | -- | -- | -- |
| SMAIO SA | 8.28m | -1.85m | 38.95m | 43.00 | -- | 5.25 | -- | 4.70 | -0.3498 | -0.3498 | 1.55 | 1.31 | 0.6265 | 0.9214 | 7.47 | 202,030.50 | -14.00 | -10.92 | -17.52 | -20.23 | 83.83 | 83.68 | -22.35 | -31.59 | 2.50 | -32.37 | 0.288 | -- | 2.12 | 69.74 | -426.41 | -- | 16.09 | -- |
| Valerio Therapeutics SA | 1.83m | -13.17m | 73.17m | 25.00 | -- | -- | -- | 39.98 | -0.0914 | -0.0914 | 0.012 | -0.0591 | 0.0735 | -- | 0.4026 | 48,157.89 | -52.95 | -33.39 | -145.21 | -42.47 | 59.34 | 78.97 | -720.27 | -631.62 | -- | -17.09 | -- | -- | -0.3889 | -16.01 | -17.57 | -- | 65.11 | -- |
| AB Science SA | 1.03m | -8.54m | 90.67m | 37.00 | -- | -- | -- | 88.29 | -0.1478 | -0.1478 | 0.0178 | -0.457 | 0.0465 | 0.4429 | 7.93 | 26,333.33 | -38.64 | -52.12 | -206.63 | -332.22 | 90.75 | 93.25 | -831.45 | -1,016.80 | 0.668 | -4.96 | -- | -- | 10.52 | -7.36 | 34.66 | -- | -16.85 | -- |
| Euroapi SA | 882.80m | -124.30m | 203.42m | 3.43k | -- | 0.2125 | -- | 0.2304 | -1.31 | -1.31 | 9.33 | 10.01 | 0.5453 | 1.29 | 5.67 | 257,526.30 | -7.68 | -4.32 | -11.36 | -5.77 | 13.71 | 14.37 | -14.09 | -7.36 | 0.7994 | -1.65 | 0.0671 | -- | -9.79 | 0.0741 | 31.15 | -- | 5.71 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Invus Public Equities Advisors LLCas of 31 Dec 2024 | 44.08m | 8.83% |
